


8th

WORLD
CONGRESS

Targeting PHAGE THERAPY 2025



A G E N D A

June 10-11, 2025

Berlin - Germany

Targeting Phage Therapy 2025

June 10 - 11, 2025 – Berlin, Germany

Day 1 - June 10, 2025

8h00 Welcoming of attendees & Badge Distribution

8h50 Welcome Note of Targeting Phage Therapy 2025

9h00 Keynote Speech



Phage Therapy 2030: Getting from Here to There

Robert T. Schooley, *University of California, San Diego, USA*

Session 1 – Phage-Bacteria Interactions & Resistance



9h30 - **Bacteriophage Therapy: A Renaissance – From Military Medicine to Civilian Healthcare**

Christian Willy, *Academic Hospital Bundeswehr Berlin, Germany*



9h55 - **Phage Defense Systems: Are They an Obstacle for Phage Therapy?**

Stan J.J. Brouns, *Delft University of Technology, The Netherlands*

10h20 Coffee Break, Networking and Poster Sessions



11h00 - **Yersinia Phage Stories: Impact on Phage Therapy**

Mikael Skurnik, *University of Helsinki, Finland*



11h25 - **Biocontrol of Phage Resistance in Pseudomonas Infections – Fitness Trade-Offs Between Phages and Antibiotic Sensitivity**

Jumpei Fujiki, *Rakuno Gakuen University, Japan*

11h50 Short Oral Presentations & Innovations

DUOFAG – Human Clinical Trial Phase I

Dana Štveráková, *MB PHARMA s.r.o., Czech Republic*

Successful Eradication of Chronic Pseudomonas Aeruginosa Infection with Personalised Bacteriophage Therapy in Children with Cystic Fibrosis: An Early Phase Clinical Trial

Jagdev Singh, *The Children's Hospital at Westmead, Australia*

A Multifaceted Experience with Phage Therapy: A Short Review of Successful and Challenging Cases across Multiple Body Systems

Mariam Dadiani, *Eliava Phage Therapy Center, Georgia*

Anti-Quorum Sensing Phages Rescue Galleria mellonella Larvae from Pseudomonas aeruginosa Infection

Kira Céline Koonce, *University of Copenhagen, Denmark*

12h30 Lunch Break, Networking, Poster & Exhibition Sessions
Group photo

Session 2 – Phage Therapy Across Systems: From Gut Ecosystems to Precision Oncology



14h00 - **Complex Phage Communities Control Gut (im)balances and May Hold the Key to Restore Gut Biosis**
Dennis Sandris Nielsen, University of Copenhagen, Denmark



14h25 - **KlebPhaCol: Novel Gut Phage Order Associated with the Human Gut**
Franklin Nobrega, University of Southampton, United Kingdom



14h50 - **Targeting Tumors with Engineered Phages: A New Frontier in Precision Oncology**
Alberto Danielli, University of Bologna, Italy



15h15 - **Engineering Phages for Cancer Therapy: Insights into Immune Interactions and Targeting in Ex-Vivo and In-Vivo Models**
Alena Kaltenbrunner, University of Bologna, Italy

15h40 Coffee Break, Networking, Poster & Exhibition Sessions

16h20 Short Oral Presentations & Innovations

PHAGE–Postbiotic Synergy: a Novel Strategy against *Pseudomonas Aeruginosa* in Burn Wound Infection in *Galleria Mellonella*
Mine Egin, Karadeniz Technical University, Turkey

Bacteriophage-based vaccine and IL-12 Gene Therapy Eradicate Aggressive Melanoma
Andrej Cör, Valdotra Orthopaedic Hospital, Slovenia

Novel Mycobacteriophages as a Promising Adjunct in the Fight Against Drug-Resistant TB and NTM Infections
Anthony Vocat, Lausanne University Hospital, Switzerland

Session 3 - Phage Therapy in Veterinary Medicine, Agricultural & Industrial Applications



16h50 - **Phage Therapy in Veterinary Medicine: Presentation of First Clinical Trial in Japan**
Hidetomo Iwano, Rakuno Gakuen University, Japan



17h15 - **Bacteriophages Applications in Broiler Farms: Strategies & Perspectives**
Sandra Sevilla, Centro de Calidad Avícola y Alimentación Animal, Spain

17h40 Short Oral Presentations & Innovations

New Insights into Bacteriophage Therapy in Dogs
Eva Maria Kalbhenn, LABOKLIN GmbH & Co. KG, Germany

In Ovo Phage Administration as a Novel Prophylactic Approach against Salmonella Typhimurium in Broiler Chickens
Jan Torres-Boncomppte, Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana, Spain

From Cells to Larvae: A Two-Front Approach to Salmonella Eradication Using Bacteriophage Vb_Sen-Miriam1
Łukasz Grabowski, University of Gdansk, Poland

Cure of a Difficult-To-Treat Pseudomonas Aeruginosa Canine Chronic Otitis Externa (Oe) with the PyoBacteriophage Cocktail Followed by Antibiotics
Raphaël Baudin, Lausanne University Hospital, Switzerland

Coevolution of Bacteriophages Enhances Biocontrol of Shiga Toxin-Producing Escherichia Coli in Food Matrix
Nicola Mangieri, University of Milan, Italy

18h30 End of Conference Day One

20h00 Speakers' Dinner (reserved for ticket holders)

Day 2 - June 11, 2025

8h25 Welcoming of attendees & Badge Distribution

8h30 Short Oral Presentations & Innovations

Addressing Phage Resistance in Pseudomonas Aeruginosa Isolates from People with Cystic Fibrosis
Federica Briani, Università degli Studi di Milano, Italy

Isolation, Characterization and Anti-Biofilm Activity of Lytic Bacteriophage K2 against Klebsiella Pneumoniae Isolates
Damla Damar Celik, Marmara University, Turkey

Collateral Effects of Bacteriophage Resistance on Antibiotic Sensitivity in Pseudomonas Aeruginosa
Laura Rianne Baars, Leiden University, Netherland

Session 4 - Innovative Phage Applications in Clinical Research



09h00 - **Translating Phage Therapy into the Clinic: Recent Accomplishments and Next Challenges**
Jeremy Barr, Monash University, Australia



09h25 - **Inhaled Bacteriophage Therapy for Multidrug Resistant Pseudomonas Aeruginosa: Advances & Perspectives**
Gail L. Stanley, Yale University, USA



9h50 - **Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery**
Christian Kühn, Hannover Medical School, Germany

10h15 Coffee Break, Networking, Poster & Exhibition Sessions

11h00 - Short Oral Presentations & Innovations

Endolysin (Lysk04) Combined with Plant-Derived Phenylpropanoid Disrupt Outer Membrane Barriers and Exhibits Broad-Spectrum Antibacterial Activity Against High-Risk Gram-Negative Pathogens
Susweta Das, Dayananda Sagar University, India

Biohybrid Composites of Platelet-Rich Fibrin and Gelatin Hydrogel Beads (Nano/Micro) for Targeted Phage Delivery in the Treatment of Infected Wounds
Farzaneh Moghtader, TiPhage, Turkey

Phage P04 Loaded Polysaccharide Hydrogel to Combat Biofilm-Forming Klebsiella Pneumoniae Infected Lesions
Harshitha N, Dayananda Sagar University, India

Antibody Alternatives from Bacterial Viruses: Phage Receptor Binding Proteins as Novel Tools for Diagnostics and Therapy of Bacterial Infections
Peter Braun, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Germany

Determining the potential of Bacteriophages to evolve their host range

Wallapat Phongtang, Friedrich-Schiller-Universität Jena, Germany

Phage-Antibiotic Composite Efficacy on Dual-Species Biofilm

Tea Glonti, Queen Astrid Military Hospital, Belgium

Freeze-Dried Tablets for Therapeutic Application of Bacteriophages

Marie Komárková, Masaryk University, Czech Republic

Source-Dependent Variability in Staphylococcus Aureus Susceptibility to Bacteriophage Infection

Hanife Nur Karakoc Parlayan, Karadeniz Technical University Trabzon, Turkey

12h20 Lunch Break, Poster & Exhibition Sessions



13h30 - **Endolysin B as a New Approach & Archetype in M. Tuberculosis Treatment**

Loris Rizzello, University of Milan, Italy



13h55 - **Ex Vivo Pig Lung as a New Cystic Fibrosis Model for the Study of Pseudomonas aeruginosa Biofilm Infection and Phage Therapy Application**

Marco Cafora, University of Milan, Italy

14h20 - Short Oral Presentations & Innovations

Novel Mycobacteriophages as a Promising Adjunct in the Fight Against Drug-Resistant TB and NTM Infections

Anthony Vocat, Lausanne University Hospital, Switzerland

Phage Heteroresistance in Clinical Klebsiella Pneumoniae Isolates: Impact of Differential Capsule Expression on Phage Efficacy

Iris Najjar, Escola Paulista de Medicina-Universidade Federal de São Paulo, Brazil

Broad-Spectrum Lytic Bacteriophages from Wastewater as Therapeutic Candidates against Antibiotic-Resistant Clinical Strains

Erva Rakici, Recep Tayyip Erdogan University, Turkey

Five Years of Adaptive Phage Therapy in the Intensive Care Unit: Prospects, Limitations, Opportunities

Ekaterina A. Chervenskaya, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Russia

Session 5 – From Bench to Market: GMP Production, Regulation & the Future of Phage Therapies



14h50 - **Phage Therapy in Europe: Legal, Regulatory, and Ethical Issues**

Barbara Brenner, Kanzlei BRENNER, Germany



15h15 **Practical Session: GMP (Good Manufacturing Practices) for phage production. Scaling production. Quality control and standardization. Market access and commercialization strategies**

Frenk Smrekar, JAFRAL, Slovenia

15h40 The Lausanne University Hospital GMP Production Pipeline for Manufacture of Therapeutic Bacteriophages

Gregory Resch, Lausanne University Hospital, Switzerland

GMP-Compliant Bacteriophage Bulk Production as APIs for Personalized Human Medicine: A European Perspective

Milan Bunata, FAGOFARMA, Czech Republic

From Biology to Business: INCATE as a Catalyst in the Antibacterial Innovation Pipeline
Mercedes Gonzalez Moreno, *Hans Knöll Institute (HKI), Germany*

AWMF Sk2 Guideline Personalized Bacteriophage Therapy in Germany
Simone Lieberknecht-Jouy, *University Hospital Frankfurt, Germany*

16h20 **Discussion – The Future Phage Therapy in Europe: The Missing Link**

- Bridging scientific, clinical, and industrial gaps
- Addressing regulatory and market challenges
- Collaboration strategies for advancing phage-based innovations

16h35 **Concluding Remarks & Awards of Targeting Phage Therapy 2025**

16h45 Networking, Accompanied by Drinks and Appetizers

17h00 **End of Targeting Phage Therapy 2025**

For more information, please visit: www.phagetherapy-site.com